Aridis' Monoclonal Antibody Rouses Analyst Optimism Despite Pneumonia Phase III Miss
Trial Size Limited
The US biotech’s lead candidate missed the mark in a Phase III hospital-related pneumonia trial due to low recruitment affected by macroeconomic headwinds but analysts retain high hopes for another upcoming study.
